Novel Biopharmaceuticals. Pharmacokinetics, Pharmacodynamics, and Bioanalytics.

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Volumn , Issue , 2013, Pages 97-137

  Marian, Melinda ^a   Seghezzi, Wolfgang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti drug antibody; Biodistribution; Immunoassay; LC MS; Ligand binding assay; Pharmacodynamic; Pharmacokinetic

Indexed keywords

EID: 84903808386     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394810-6.00004-6     Document Type: Chapter

References (225)

1. Meibohm B., Braeckman R. Pharmacokinetics and pharmacodynamics of peptide and protein drugs. Pharmaceutical Biotechnology 2008, 95-123. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
2. McDonald T.A., Zepeda M.L., Tomlinson M.J., Bee W.H., Ivens I.A. Subcutaneous administration of biotherapeutics: Current experience in animal models. Curr Opin Mol Ther 2010, 12:461-470.
3. Porter C.J., Charman W.N. Transport and absorption of drugs via the lymphatic system. Adv Drug Deliv Rev 2001, 50:1-2.
4. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990, 7:167-169.
5. Wang W., Chen N., Shen X., Cunningham P., Fauty S., Michel K., et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 2012, 40:952-962.
6. Mrsny R.J. Metabolic processes at injection sites affecting pharmacokinetics, pharmacodynamics, and metabolism of protein and peptide therapeutics. Proteins and Peptides 2011, 80-105. Informa Healthcare, New York.
7. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008, 84:548-558.
8. Lobo E.D., Hansen R.J., Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004, 93:2645-2668.
9. Tang L., Persky A.M., Hochhaus G., Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004, 93:2184-2204.
10. Foote M. Hematopoietic growth factors. Pharmaceutical Biotechnology 2008, 225-242. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
11. Ryff J.-C., Bordens R.W., Pestka S. Interferons and Interleukins. Pharmaceutical Biotechnology 2008, 243-264. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
12. Beals J.M., DeFelippis M.R., Kovach P.M. Insulin. Pharmaceutical Biotechnology 2008, 265-280. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
13. Marian M., Oeswein J.Q. Growth Hormones. Pharmaceutical Biotechnology 2008, 281-291. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
14. Modi N.B. Recombinant coagulation factors and thrombolytic agents. Pharmaceutical Biotechnology 2008, 293-307. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
15. Lazarus R.A., Wagener J.S. Recombinant human deoxyribonuclease I. Pharmaceutical Biotechnology 2008, 388-398. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
16. Sam T. Follicle-stimulating hormone. Pharmaceutical Biotechnology 2008, 399-403. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
17. Tabrizi M., Bornstein G.G., Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 2009, 12:33-43.
18. Ternant D., Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005, 5(Suppl. 1):S37-47.
19. Tabrizi M.A., Tseng C.M., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11:81-88.
20. Ward E.S., Ober R.J. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 2009, 103:77-115.
21. Alvarez H.M., So O.Y., Hsieh S., Shinsky-Bjorde N., Ma H., Song Y., et al. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice. Drug Metab Dispos 2012, 40:360-373.
22. Correia I.R. Stability of IgG isotypes in serum. mAbs 2010, 2:221-232.
23. Tao M.H., Morrison S.L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989, 143:2595-2601.
24. Harris R.J. Heterogeneity of recombinant antibodies: Linking structure to function. Dev Biol 2005, 122:117-127.
25. Boswell C.A., Tesar D.B., Mukhyala K., Theil F.P., Fielder P.J., Khawli L.A. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010, 21:2153-2163.
26. Khawli L.A., Goswami S., Hutchinson R., Kwong Z.W., Yang J., Wang X., et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2010, 2:613-624.
27. Igawa T., Tsunoda H., Tachibana T., Maeda A., Mimoto F., Moriyama C., et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010, 23:385-392.
28. Covell D.G., Barbet J., Holton O.D., Black C.D., Parker R.J., Weinstein J.N. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986, 46:3969-3978.
29. Bazin-Redureau M.I., Renard C.B., Scherrmann J.M. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 1997, 49:277-281.
30. Kim J.K., Tsen M.F., Ghetie V., Ward E.S. Evidence that the hinge region plays a role in maintaining serum levels of the murine IgG1 molecule. Mol Immunol 1995, 32:467-475.
31. Chen X., Zaro J.L., Shen W.C. Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol 2012, 8:581-595.
32. Edwards A., Daniels B.S., Deen W.M. Ultrastructural model for size selectivity in glomerular filtration. Am J Physiol 1999, 276:F892-902.
33. Maack T., Johnson V., Kau S.T., Figueiredo J., Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review. Kidney Int 1979, 16:251-270.
34. Cumming D.A. Glycosylation of recombinant protein therapeutics: Control and functional implications. Glycobiology 1991, 1:115-130.
35. Marks D.L., Gores G.J., LaRusso N.F. Hepatic processing of peptides. Peptide-based Drug Design: Controlling Transport and Metabolism 1995, 221-248. American Chemical Society, Washington, DC. M.D. Taylor, G.L. Amidon (Eds.).
36. Levy G. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 1994, 56:356-358.
37. Mager D.E. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006, 72:1-10.
38. Dayde D., Ternant D., Ohresser M., Lerondel S., Pesnel S., Watier H., et al. Tumor burden influences exposure and response to rituximab: Pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009, 113:3765-3772.
39. 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002, 29:1276-1282.
40. R(rituxiamb): US prescribing information 2012, Biogen IDEC, Inc. and Genentech, Inc., Weston, MA.
41. Mould D.R., Davis C.B., Minthorn E.A., Kwok D.C., Elliott M.J., Luggen M.E., et al. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 1999, 66:246-257.
42. R (trastuzumab): US prescribing information 2002, Genentech, Inc., South San Francisco, CA.
43. Anand B., Deng R., Theil F.-P., Li J., Jumbe S., Gelzleichter T., et al. Monoclonal antibodies: From structure to therapeutic application. Pharmaceutical Biotechnology 2008, 309-337. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
44. Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 2011, 50:295-306.
45. Agoram B., Heatherington A.C., Gastonguay M.R. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 2006, 8:E552-563.
46. Ramakrishnan R., Cheung W.K., Wacholtz M.C., Minton N., Jusko W.J. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004, 44:991-1002.
47. Bauer R.J., Dedrick R.L., White M.L., Murray M.J., Garovoy M.R. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Pharmacodyn 1999, 27:397-420.
48. Roskos L.K., Lum P., Lockbaum P., Schwab G., Yang B.B. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006, 46:747-757.
49. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011, 22:868-876.
50. Chen C., Constantinou A., Deonarain M. Modulating antibody pharmacokinetics using hydrophilic polymers. Expert Opin Drug Deliv 2011, 8:1221-1236.
51. Macdougall I.C., Gray S.J., Elston O., Breen C., Jenkins B., Browne J., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999, 10:2392-2395.
52. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
53. Dall'Acqua W.F., Kiener P.A., Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006, 281:23514-23524.
54. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
55. Smith B.J., Popplewell A., Athwal D., Chapman A.P., Heywood S., West S.M., et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 2001, 12:750-756.
56. Shen B.Q., Xu K., Liu L., Raab H., Bhakta S., Kenrick M., et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012, 30:184-189.
57. Evans M., Schumm-Draeger P.M., Vora J., King A.B. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: Improvements and limitations. Diabetes Obes Metab 2011, 13:677-684.
58. Davies M.J., Kela R., Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011, 13:207-220.
59. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.
60. Dennis M.S., Jin H., Dugger D., Yang R., McFarland L., Ogasawara A., et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007, 67:254-261.
61. Johansson A., Erlandsson A., Eriksson D., Ullen A., Holm P., Sundstrom B.E., et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002, 94:1306-1313.
62. Montero-Julian F.A., Klein B., Gautherot E., Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: Enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995, 85:917-924.
63. Pasquetto M.V., Vecchia L., Covini D., Digilio R., Scotti C. Targeted drug delivery using immunoconjugates: Principles and applications. J Immunother 2011, 34:611-628.
64. Boswell C.A., Mundo E.E., Zhang C., Bumbaca D., Valle N.R., Kozak K.R., et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011, 22:1994-2004.
65. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs 2012, 4(2).
66. Thakur A., Lum L.G. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 2010, 12:340-349.
67. Chames P., Baty D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel?. mAbs 2009, 1:539-547.
68. Muller D., Kontermann R.E. Bispecific antibodies for cancer immunotherapy: Current Perspectives. BioDrugs 2010, 24:89-98.
69. Ruf P., Kluge M., Jager M., Burges A., Volovat C., Heiss M.M., et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 2010, 69:617-625.
70. Nagorsen D., Kufer P., Baeuerle P.A., Bargou R. Blinatumomab: A historical perspective. Pharmacol Ther 2012, 136:334-342.
71. Dong J., Sereno A., Snyder W.B., Miller B.R., Tamraz S., Doern A., et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011, 286:4703-4717.
72. Muller D., Kontermann R.E. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007, 9:319-326.
73. Stork R., Zettlitz K.A., Muller D., Rether M., Hanisch F.G., Kontermann R.E. N-Glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008, 283:7804-7812.
74. Hamuro L.L., Kishnani N.S. Metabolism of biologics: Biotherapeutic proteins. Bioanalysis 2012, 4:189-195.
75. Prueksaritanont T., Tang C. ADME of biologics-what have we learned from small molecules?. AAPS J 2012, 14(3):410-419.
76. Fox J.A., Hotaling T.E., Struble C., Ruppel J., Bates D.J., Schoenhoff M.B. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996, 279:1000-1008.
77. 125I-labeled therapeutic proteins: Application in protein drug development beyond oncology. J Pharm Sci 2010, 99:1028-1045.
78. Xiang H., Nguyen C.B., Kelley S.K., Dybdal N., Escandon E. Tissue distribution, stability, and pharmacokinetics of Ap02 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COL0205 tumor-bearing nude mice. Drug Metab Dispos 2004, 32:1230-1238.
79. Nguyen C.B., Harris L., Szonyi E., Baughman S.A., Hale V.G., Dybdal N.O., et al. Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys. Drug Metab Dispos 2000, 28:598-607.
80. Coffey G.P., Fox J.A., Pippig S., Palmieri S., Reitz B., Gonzales M., et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005, 33:623-629.
81. Hoppin J., Orcutt K.D., Hesterman J.Y., Silva M.D., Cheng D., Lackas C., et al. Assessing antibody pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther 2011, 337:350-358.
82. Schellekens H., Jiskoot W. Immunogenicity of therapeutic proteins. Pharmaceutical Biotechnology 2008, 124-132. Informa Healthcare, New York. D.J.A. Crommenlin, R.D. Sindelar, B. Meibohm (Eds.).
83. Chirmule N., Jawa V., Meibohm B. Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy. AAPS J 2012, 14:296-302.
84. Wagner C.L., Schantz A., Barnathan E., Olson A., Mascelli M.A., Ford J., et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003, 112:37-53.
85. Anderson P.J. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005, 34:19-22.
86. Rehlaender B.N., Cho M.J. Antibodies as carrier proteins. Pharm Res 1998, 15:1652-1656.
87. Rosenblum M.G., Unger B.W., Gutterman J.U., Hersh E.M., David G.S., Frincke J.M. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res 1985, 45:2421-2424.
88. Working P. Potential effects of antibody induction by protein drugs. Protein Pharmacokinetics and Metabolism 1992, 73-92. Plenum Press, New York. B. Ferraiolo, M.A. Mohler, C.A. Gloff (Eds.).
89. US Department of Health and Human Services Draft Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. US Department of Health and Human Services 2013, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Washington, DC.
90. Rojas J.R., Taylor R.P., Cunningham M.R., Rutkoski T.J., Vennarini J., Jang H., et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005, 313:578-585.
91. van der Laken C.J., Voskuyl A.E., Roos J.C., Stigter van Walsum M., de Groot E.R., et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007, 66:253-256.
92. R (agalsidase beta): US prescribing information 2010, Genzyme Corporation, Cambridge, MA.
93. Swann P.G., Tolnay M., Muthukkumar S., Shapiro M.A., Rellahan B.L., Clouse K.A. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008, 20:493-499.
94. Tabrizi M.A., Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007, 12:540-547.
95. Gerlowski L.E., Jain R.K. Physiologically based pharmacokinetic modeling: Principles and applications. J Pharm Sci 1983, 72:1103-1127.
96. Baxter L.T., Zhu H., Mackensen D.G., Butler W.F., Jain R.K. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995, 55:4611-4622.
97. Mould D.R., Sweeney K.R. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007, 10:84-96.
98. Deng R., Jin F., Prabhu S., Iyer S. Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development?. Expert Opin Drug Metab Toxicol 2012, 8:141-160.
99. Mahmood I., Green M.D. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005, 44:331-347.
100. Agoram B.M., Martin S.W., van der Graaf P.H. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today 2007, 12:1018-1024.
101. Meibohm B., Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997, 35:401-413.
102. Racine-Poon A., Botta L., Chang T.W., Davis F.M., Gygax D., Liou R.S., et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 1997, 62:675-690.
103. Radwanski E., Chakraborty A., Van Wart S., Huhn R.D., Cutler D.L., Affrime M.B., et al. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 1998, 15:1895-1901.
104. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Pharmacodyn 1993, 21:457-478.
105. Zia-Amirhosseini P., Minthorn E., Benincosa L.J., Hart T.K., Hottenstein C.S., Tobia L.A., et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 1999, 291:1060-1067.
106. Sun Y.N., Lee H.J., Almon R.R., Jusko W.J. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. J Pharmacol Exp Ther 1999, 289:1523-1532.
107. Benincosa L.J., Chow F.S., Tobia L.P., Kwok D.C., Davis C.B., Jusko W.J. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 2000, 292:810-816.
108. Danhof M., de Lange E.C., Della Pasqua O.E., Ploeger B.A., et al. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008, 29:186-191.
109. Mager D.E., Wyska E., Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003, 31:510-518.
110. Perez-Ruixo J.J., Kimko H.C., Chow A.T., Piotrovsky V., Krzyzanski W., Jusko W.J. Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn 2005, 32:767-793.
111. Nagaraja N.V., Pechstein B., Erb K., Klipping C., Hermann R., Locher M., et al. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. J Clin Pharmacol 2003, 43:243-251.
112. Marathe D.D., Marathe A., Mager D.E. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos 2011, 32:471-481.
113. Lemaire V., Tobin F.L., Greller L.D., Cho C.R., Suva L.J. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 2004, 229:293-309.
114. Tabrizi M., Funelas C., Suria H. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J 2010, 12:592-601.
115. Lowe P.J., Tannenbaum S., Wu K., Lloyd P., Sims J. On setting the first dose in man: Quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 2010, 106:195-209.
116. Wang W., Prueksaritanont T. Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Biopharm Drug Dispos 2010, 31:253-263.
117. Ling J., Zhou H., Jiao Q., Davis H.M. Interspecies scaling of therapeutic monoclonal antibodies: Initial look. J Clin Pharmacol 2009, 49:1382-1402.
118. Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 2009, 98:3850-3861.
119. Deng R., Iyer S., Theil F.P., Mortensen D.L., Fielder P.J., Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?. mAbs 2011, 3:61-66.
120. Dong J.Q., Salinger D.H., Endres C.J., Gibbs J.P., Hsu C.P., Stouch B.J., et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011, 50:131-142.
121. Mahmood I. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 2004, 93:177-185.
122. Urva S.R., Yang V.C., Balthasar J.P. Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody. J Pharm Sci 2010, 99:1582-1600.
123. US Department of Health and Human Services Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trails for Therapeutics in Adult Health Volunteers 2005, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC.
124. European Medicines Agency Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products 2007, European Medicines Agency, London.
125. Tabrizi M.A., Bornstein G.G., Klakamp S.L., Drake A., Knight R., Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 2009, 14:298-305.
126. Yu J., Karcher H., Feire A.L., Lowe P.J. From target selection to the minimum acceptable biological effect level for human study: Use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 2011, 13:169-178.
127. Gibbs J.P. Prediction of exposure-response relationships to support first-in-human study design. AAPS J 2010, 12:750-758.
128. Betts A.M., Clark T.H., Yang J., Treadway J.L., Li M., Giovanelli M.A., et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010, 333:2-13.
129. Zheng Y., Scheerens H., Davis J.C., Deng R., Fischer S.K., Woods C., et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 2011, 89:283-290.
130. Nowatzke W.L., Rogers K., Wells E., Bowsher R.R., Ray C., Unger S. Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. Bioanalysis 2011, 3:509-521.
131. Shah V.P., Bansal S. Historical perspective on the development and evolution of bioanalytical guidance and technology. Bioanalysis 2011, 3:823-827.
132. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., et al. Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective. J Pharm Biomed Anal 2000, 21:1249-1273.
133. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003, 20:1885-1900.
134. Miller K.J., Bowsher R.R., Celniker A., Gibbons J., Gupta S., Lee J.W., et al. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm Res 2001, 18:1373-1383.
135. Smolec J., DeSilva B., Smith W., Weiner R., Kelly M., Lee B., et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm Res 2005, 22:1425-1431.
136. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289:1-16.
137. Shankar G., Shores E., Wagner C., Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006, 24:274-280.
138. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007, 321:1-18.
139. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008, 333:1-9.
140. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008, 48:1267-1281.
141. Lee J.W., Weiner R.S., Sailstad J.M., Bowsher R.R., Knuth D.W., O'Brien P.J., et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: A conference report. Pharm Res 2005, 22:499-511.
142. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006, 23:312-328.
143. US Department of Health and Human Services Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 2001, Center for Veterinary Medicine, Washington, DC.
144. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm Res 2007, 24:1962-1973.
145. van Amsterdam P., Arnold M., Bansal S., Fast D., Garofolo F., Lowes S., et al. Building the Global Bioanalysis Consortium-working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation. Bioanalysis 2010, 2:1801-1803.
146. Millipore E.M.D. Data Sheet ELISA & RIA Kits. EMD Millipore, St. Charles, Missouri [accessed April 2012]. http://www.millipore.com/ELISA.
147. Mesoscale Technology http://www.mesoscale.com/CatalogSystemWeb/WebRoot/technology/ecl.htm.
148. PerkinElmer Alpha Technology [accessed April 2012]. http://www.perkinelmer.com/CMSResources/Images/44-127981BRO_AlphaTechnology.pdf.
149. Gyros Immunoassay platform [accessed April 2012]. http://www.gyros.com/en/products.
150. Biacore Technical information [accessed April 2012]. http://www.Biacore.com.
151. Niemeyer C.M., Adler M., Wacker R. Detecting antigens by quantitative immuno-PCR. Nature Protocols 2007, 2:1918-1930.
152. Adler M., Wacker R., Niemeyer C.M. Sensitivity by combination: Immuno-PCR and related technologies. The Analyst 2008, 133:702-718.
153. Chimera Biotec IMPERACER Technology [accessed April 2012]. http://www.chimera-biotec.de.
154. Spengler M., Adler M., Jonas A., Niemeyer C.M. Immuno-PCR assays for immunogenicity testing. Biochem Biophys Res Commun 2009, 387:278-282.
155. Singer D., Soininen H., Alafuzoff I., Hoffmann R. Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease. Anal Bioanal Chem 2009, 395:2263-2267.
156. Huber R., Eisenbraun J., Miletzki B., Adler M., Scheer R., Klein R., et al. Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. Eur J Clin Pharmacol 2010, 66:889-897.
157. Olink Bioscience Proseek Technology [accessed April 2012]. http://www.olink.com.
158. Lundberg M., Eriksson A., Tran B., Assarsson E., Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 2011, 39:e102.
159. Mikulskis A., Yeung D., Subramanyam M., Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J Immunol Methods 2011, 365:38-49.
160. Myler H.A., Given A., Kolz K., Mora J.R., Hristopoulos G. Biotherapeutic bioanalysis: A multi-indication case study review. Bioanalysis 2011, 3:623-643.
161. Lee J.W., Kelley M., King L.E., Yang J., Salimi-Moosavi H., Tang M.T., et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: Technical challenges and PK/PD applications over the course of drug development. AAPS J 2011, 13:99-110.
162. Campbell J.L., Le Blanc J.C. Peptide and protein drug analysis by MS: Challenges and opportunities for the discovery environment. Bioanalysis 2011, 3:645-657.
163. van den Broek I., Sparidans R.W., Schellens J.H., Beijnen J.H. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr 2008, 872:1-22.
164. Ezan E., Dubois M., Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. The Analyst 2009, 134:825-834.
165. Damen C.W., Schellens J.H., Beijnen J.H. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Hum Antibodies 2009, 18:47-73.
166. Brun V., Dupuis A., Adrait A., Marcellin M., Thomas D., Court M., et al. Isotope-labeled protein standards: Toward absolute quantitative proteomics. Mol Cell Proteomics 2007, 6:2139-2149.
167. Li H., Ortiz R., Tran L., Hall M., Spahr C., Walker K., et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem 2012, 84:1267-1273.
168. Chen G., Warrack B.M., Goodenough A.K., Wei H., Wang-Iverson D.B., Tymiak A.A. Characterization of protein therapeutics by mass spectrometry: Recent developments and future directions. Drug Discov Today 2011, 16:58-64.
169. Hall M.P., Gegg C., Walker K., Spahr C., Ortiz R., Patel V., et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: Strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 2010, 12:576-585.
170. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991, 16:249-255.
171. Xu Y., Mehl J.T., Bakhtiar R., Woolf E.J. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal Chem 2010, 82:6877-6886.
172. Kuang B., King L., Wang H.F. Therapeutic monoclonal antibody concentration monitoring: Free or total?. Bioanalysis 2010, 2:1125-1140.
173. O'Hara D.M., Theobald V., Egan A.C., Usansky J., Krishna M., Terwee J., et al. Ligand binding assays in the 21st century laboratory: Recommendations for characterization and supply of critical reagents. AAPS J 2012, 14:316-328.
174. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
175. Colburn W.A. Biomarkers in drug discovery and development: From target identification through drug marketing. J Clin Pharmacol 2003, 43:329-341.
176. Putnam W.S., Li J., Haggstrom J., Ng C., Kadkhodayan-Fischer S., Cheu M., et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J 2008, 10:425-430.
177. Hayashi N., Tsukamoto Y., Sallas W.M., Lowe P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007, 63:548-561.
178. Salimi-Moosavi H., Lee J., Desilva B., Doellgast G. Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. J Pharm Biomed Anal 2010, 51:1128-1133.
179. Shankar G., Pendley C., Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007, 25:555-561.
180. Dodge R., Daus C., Yaskanin D. Challenges in developing antidrug antibody screening assays. Bioanalysis 2009, 1:699-704.
181. Geng D., Shankar G., Schantz A., Rajadhyaksha M., Davis H., Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 2005, 39:364-375.
182. Mason S., La S., Mytych D., Swanson S.J., Ferbas J. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin 2003, 19:651-659.
183. Rup B., O'Hara D. Critical ligand binding reagent preparation/selection: When specificity depends on reagents. AAPS J 2007, 9:E148-155.
184. Smith H.W., Butterfield A., Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol 2007, 49:230-237.
185. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005, 304:189-195.
186. Dubois M., Fenaille F., Clement G., Lechmann M., Tabet J.C., Ezan E., et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008, 80:1737-1745.
187. Heudi O., Barteau S., Zimmer D., Schmidt J., Bill K., Lehmann N., et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 2008, 80:4200-4207.
188. Eli Lilly and Company Glucagon for Injection: US prescribing information 2004, Eli Lilly and Company, Indianapolis, IN.
189. P (insulin lispro injection): US prescribing information 2011, Eli Lilly and Company, Indianapolis, IN.
190. R (alteplase): US prescribing information 2005, Genentech, Inc., South San Francisco, CA.
191. R (epoetin alpha): US prescribing information 2011, Amgen, Inc., Thousand Oaks, CA.
192. R (filgastrim): US prescribing information 2006, Amgen, Inc., Thousand Oaks, CA.
193. R A(Interferon alpha 2a): US prescribing information 2006, Hoffman-LaRoche, Inc, Nutley, NJ.
194. R (Interferon beta 1-b): US prescribing information 2003, Berlex Laboratories, Montville, NJ.
195. R (somatropin): US prescribing information 2007, Genentech, Inc., South San Francisco, CA.
196. R (Peg Interferon alpha-2b): US prescribing information 2011, Schering Corporation, Whitehouse Station, NJ.
197. R (peg interferon alpha-2a): US prescribing information 2011, Genentech, Inc., South San Francisco, CA.
198. R (darbepoetin alpha): US prescribing information 2011, Amgen, Inc., Thousand Oaks, CA.
199. R (adalimumab): US prescribing information 2002, Abbott Laboratories, North Chicago, IL.
200. R (bevacizumab): US prescribing information 2009, Genentech, Inc., South San Francisco, CA.
201. R (belimumab): US prescribing information 2012, Human Genome Sciences, Inc., Rockville, MD.
202. R (daclizumab): US prescribing information 2005, Hoffman-LaRoche, Nutley, NJ.
203. R (denosumab): US prescribing information 2010, Amgen, Inc., Thousand Oaks, CA.
204. R (efalizumab): US prescribing information 2004, Genentech, Inc., South San Francisco, CA.
205. R (golimumab): US prescribing information 2011, Janssen Biotech, Inc., Horsham, PA.
206. R (ipilimumab): US prescribing information 2011, Bristol-Meyers Squibb Company, Princeton, NJ.
207. R (omalizumab): US prescribing information 2007, Genentech, Inc., South San Francisco, CA.
208. R (palivizumab): US prescribing information 2012, MedImmune LLC, Gaithersberg, MD.
209. R (panitumumab): US prescribing information 2008, Amgen, Inc., Thousand Oaks, CA.
210. R (natalizumab): US prescribing information 2006, Biogen IDEC Inc., Cambridge, MA.
211. R (ustekimumab): US prescribing information 2010, Centocor Ortho Biotech, Inc., Horsham, PA.
212. R (basiliximab): Summary of Product Characteristics EMA 2012, Novartis Europharm Limited, Horsham, West Sussex.
213. R (cetuximab): US prescribing information 2012, ImClone LLC, Branchburg, NJ.
214. R (infliximab): US prescribing information 2011, Centocor, Inc., Malvern, PA.
215. R (abatacept): US prescribing information 2012, Bristol-Meyers Squibb Company, Princeton, NJ.
216. R (alefacept): US prescribing information 2012, Astellas Pharma US Inc., Deerfield, IL.
217. R (belatacept): US prescribing information 2011, Bristol-Meyers Squibb Company, Princeton, NJ.
218. R (entanercept): US prescribing information 2009, Immunex Corporation, Thousand Oaks, CA.
219. R (gemtuzumab ozogamicin): US prescribing information 2010, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
220. R (brentuximab vedotin): US prescribing information 2012, Seattle Genetics Inc., Bothell, WA.
221. Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28:2698-2704.
222. R (abciximab): US prescribing information 1997, Centocor, Inc., Malvern, PA.
223. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999, 17:780-783.
224. R (cetrolizumab pegol): US prescribing information 2012, UCB, Inc., Smyrna, GA, USA.
225. Ackermann B.L., Berna M.J. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007, 4:175-186.